Related Experiment Video
Updated: Sep 20, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment
Yoshihiro Morimoto1, Atsushi Fushimi1, Nami Yamashita1
1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Abstract:
Merkel cell carcinoma (MCC) is an aggressive malignancy with neuroendocrine (NE) features, limited treatment options, and a lack of druggable targets. There is no reported involvement of the MUC1-C oncogenic protein in MCC progression. We show here that MUC1-C is broadly expressed in MCCs and at higher levels in Merkel cell polyomavirus (MCPyV)-positive (MCCP) relative to MCPyV-negative (MCCN) tumors. Our results further demonstrate that MUC1-C is expressed in MCCP, as well as MCCN, cell lines and regulates common sets of signaling pathways related to RNA synthesis, processing, and transport in both subtypes. Mechanistically, MUC1-C (i) interacts with MYCL, which drives MCC progression, (ii) is necessary for expression of the OCT4, SOX2, KLF4, MYC, and NANOG pluripotency factors, and (iii) induces the NEUROD1, BRN2 and ATOH1 NE lineage dictating transcription factors. We show that MUC1-C is also necessary for MCCP and MCCN cell survival by suppressing DNA replication stress, the p53 pathway, and apoptosis. In concert with these results, targeting MUC1-C genetically and pharmacologically inhibits MCC self-renewal capacity and tumorigenicity. These findings demonstrate that MCCP and MCCN cells are addicted to MUC1-C and identify MUC1-C as a potential target for MCC treatment.
Insights
MUC1-C oncogenic protein drives Merkel cell carcinoma (MCC) progression by regulating key pathways and transcription factors. Targeting MUC1-C inhibits MCC growth, revealing it as a promising therapeutic target for this aggressive cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Merkel cell carcinoma (MCC) is an aggressive neuroendocrine cancer with limited treatment options.
- The role of the MUC1-C oncogenic protein in MCC has not been previously established.
- Understanding MCC pathogenesis is crucial for developing effective therapies.
Purpose of the Study:
- To investigate the expression and function of MUC1-C in Merkel cell carcinoma.
- To determine the role of MUC1-C in regulating signaling pathways and transcription factors critical for MCC.
- To evaluate MUC1-C as a potential therapeutic target for MCC.
Main Methods:
- Analysis of MUC1-C expression in MCC tumors and cell lines (MCPyV-positive and -negative).
- Investigated MUC1-C interactions with MYCL and its regulation of pluripotency and neuroendocrine transcription factors.
- Assessed the impact of MUC1-C targeting on MCC cell survival, DNA replication stress, p53 pathway, and apoptosis.
- Evaluated the effect of genetic and pharmacological MUC1-C inhibition on MCC self-renewal and tumorigenicity.
Main Results:
- MUC1-C is broadly expressed in MCC, with higher levels in MCPyV-positive tumors.
- MUC1-C regulates common signaling pathways involved in RNA synthesis, processing, and transport in both MCC subtypes.
- MUC1-C interacts with MYCL, induces key pluripotency and neuroendocrine transcription factors, and suppresses apoptosis and DNA replication stress.
- Targeting MUC1-C inhibits MCC self-renewal and tumorigenicity.
Conclusions:
- Merkel cell carcinoma cells are dependent on MUC1-C for survival and progression.
- MUC1-C plays a critical role in regulating essential cellular processes in MCC.
- MUC1-C represents a promising therapeutic target for Merkel cell carcinoma treatment.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:23Abnormal Proliferation